Read more
This book is a scientific compendium documenting the state of the art in the discovery and development of vaccines, monoclonal antibodies, and enzymes for the treatment of Substance Use Disorders (SUDs). The book gives detailed consideration to some of the most cutting edge topics in addiction medicine, including vaccines for nicotine, cocaine, heroin, and methamphetamine dependence; monoclonal antibodies against cocaine, methamphetamine, and phencyclidine; and the enzymes butyrylcholinesterase and cocaine esterase. In addition, the text covers a wide range of new strategies designed to optimize the development and efficacy of biologics. Unlike any other resource, this book reviews how biologics offer exciting new therapeutic opportunities for various psychiatric conditions.
Written by experts in the field, Biologics to Treat Substance Use Disorders is as an authoritative reference for psychiatrists, psychologists, and all other medical professionals working with patients suffering from Substance Use Disorders.
List of contents
Introduction.- PART I: Vaccines: Introduction.- Nicotine.- Cocaine.- Heroin.- Metamphetamine.- PART II: Monoclonal antibodies: Introduction.- Cocaine.- Metamphetamine.- PCP.- PART III: Enzymes: Introduction.- Butyrylcholinesterase.- Cocaine Esterase.- PART IV: New strategies to optimize the development of biologics: Adenovirus based vaccines.- Nanotechnology based vaccines.- Protein Nanoparticles.- DNA Scaffolded Vaccines.- Single Hapten Conjugate Therapeutic Vaccine.- Vaccine Adjuvants.- Laser Adjuvant.- Peptide Conjugates & Cytokine Adjuvants.- T. brucei: A Platform for Immunization.- Vaccines for SUDs and HIV infection.- New Monoclonal Antibodies.- Protein Engineered for Controlled Duration of Action.- PART V: Ethical aspects of biologics to treat SUDs.
About the author
Ivan D. MontoyaNational Institutes of Health, Bethesda, USA
Summary
This book is a scientific compendium documenting the state of the art in the discovery and development of vaccines, monoclonal antibodies, and enzymes for the treatment of Substance Use Disorders (SUDs). The book gives detailed consideration to some of the most cutting edge topics in addiction medicine, including vaccines for nicotine, cocaine, heroin, and methamphetamine dependence; monoclonal antibodies against cocaine, methamphetamine, and phencyclidine; and the enzymes butyrylcholinesterase and cocaine esterase. In addition, the text covers a wide range of new strategies designed to optimize the development and efficacy of biologics. Unlike any other resource, this book reviews how biologics offer exciting new therapeutic opportunities for various psychiatric conditions.
Written by experts in the field, Biologics to Treat Substance Use Disorders is as an authoritative reference for psychiatrists, psychologists, and all other medical professionals working with patients suffering from Substance Use Disorders.
Additional text
“The intended audience is psychiatrists, pharmacologists, immunologists, counselors, toxicologists, social workers, addiction specialists, and all medical professionals working with patients with drug addictions. … This is the first book, and a most comprehensive one, about the research and development of biologics to treat substance use disorders and overdose. Hopefully, biologics will be part of the therapeutic armamentarium that healthcare providers can use in the treatment of their patients with these disorders.” (Michael Easton, Doody's Book Reviews, June, 2016)
Report
"The intended audience is psychiatrists, pharmacologists, immunologists, counselors, toxicologists, social workers, addiction specialists, and all medical professionals working with patients with drug addictions. ... This is the first book, and a most comprehensive one, about the research and development of biologics to treat substance use disorders and overdose. Hopefully, biologics will be part of the therapeutic armamentarium that healthcare providers can use in the treatment of their patients with these disorders." (Michael Easton, Doody's Book Reviews, June, 2016)
